Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study

Teva reports positive Phase 2a data for TEV '408 in celiac disease

AstraZeneca completes global licence agreement for Zegfrovy

AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer

Lilly to acquire Merida Biosciences in USD2.875bn deal

Formosa Pharmaceuticals submits Clinical Trial Application to European regulatory authorities for TSY-110

Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30

GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems

Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk

Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine

Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial

DualityBio agrees global collaboration and licensing deal with Genentech

AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease

AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial

Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis